Abstract
Galactosemia is a metabolic disorder caused by mutations in the GALT gene [1,2]. We encountered a patient heterozygous for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]. Reminiscent of patients with the S135L mutation, our patient had loss of GALT enzyme activity in erythrocytes but a very mild clinical phenotype [3–8]. We performed splicing experiments and computational structural analyses to investigate the role of the novel S222N variant. Alamut software data predicted loss of splicing enhancers for the S222N and S135L mutations [9,10]. A cDNA library was generated from our patient׳s RNA to investigate for splicing errors, but no change in transcript length was seen [3]. In silico structural analysis was performed to investigate enzyme stability and attempt to understand the mechanism of the atypical galactosemia phenotype. Stability results are publicly available in the GALT Protein Database 2.0 [11–14]. Animations were created to give the reader a dynamic view of the enzyme structure and mutation locations. Protein database files and python scripts are included for further investigation.
Highlights
Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia
Our data is based on a single case of atypical galactosemia caused by compound heterozygosity for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]
The patient presented to our clinic at age 17 with no stigmata of galactosemia to determine his disease status [15]
Summary
Our data is based on a single case of atypical galactosemia caused by compound heterozygosity for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]. Confirmation of absent GALT enzyme activity, was treated with a galactose-restricted diet until the age of 3 with no symptoms, and was later lost to follow-up. The patient presented to our clinic at age 17 with no stigmata of galactosemia (apart from mild anxiety) to determine his disease status [15]. Testing revealed nearly complete absence of GALT enzyme activity in erythrocytes without any increase in the clinical biomarkers of galactosemia, galactose-1-phosphate and galactitol [16,17]. Sequencing revealed compound heterozygosity for H132Q and S222N mutations. Given the ability of our patient to oxidize galactose in tissues other than red blood cells, as evidenced by galactose-1-phosphate and galactitol levels in the normal range, we suspected a splicing defect. Differential splicing seemed a reasonable explanation for differential tissue activity of the GALT enzyme
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have